Clinical Trials Logo

Clinical Trial Summary

This research study is looking to see how well male breast cancer responds to preoperative treatment with endocrine therapy and which endocrine therapy regimen is the most effective treatment for male breast cancer. The drugs used in this study are: - Tamoxifen - Anastrozole - Degarelix - Abemaciclib


Clinical Trial Description

This is an open-label, multicenter, randomized trial for men with stage I-III hormone receptor-positive (HR+)/HER2-negative breast cancer. The trial will have two phases: A 3-week window phase containing endocrine therapy followed by a 4-month treatment phase where participants are treated with one of four endocrine therapy treatment combinations. Tamoxifen is the standard of care for the treatment of breast cancer in men. Anastrozole is a standard treatment in women with breast cancer and works more effectively than tamoxifen. This study hopes to learn if anastrozole may also be effective in men. Given that gonadal suppression and CDK 4/6 inhibitors have both improved treatment in women with breast cancer, the study hopes to learn how the addition of Degarelix (gonadal suppression) and Abemaciclib (CDK 4/6 inhibitors) work in comparison to standard of care tamoxifen. The research study procedures include screening for eligibility and study treatment including laboratory evaluations and quality of life questionnaires. After completion of treatment, participants will be followed for up to 10 years It is expected that about 60 men will take part in this research study. Eli Lilly, a pharmaceutical company, is supporting this research study by providing one of the study drugs. This study is also being supported by Johns Hopkins University on behalf of the Translational Breast Cancer Research Consortium (TBCRC). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05501704
Study type Interventional
Source Dana-Farber Cancer Institute
Contact Jose Pablo Leone, MD
Phone 617-789-2903
Email josep_leone@dfci.harvard.edu
Status Recruiting
Phase Phase 2
Start date October 11, 2023
Completion date April 1, 2036

See also
  Status Clinical Trial Phase
Active, not recruiting NCT02480933 - Silent Breast Cancer A Study of the Disease Prevalence Held by Imaging Guided Biopsies in Autopsy Specimens N/A
Terminated NCT01705340 - Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery Phase 1
Terminated NCT01222377 - Endoscopic Breast Surgery in Treating Patients With Breast Cancer N/A
Completed NCT00425672 - ONTAK® in Treating Patients With Advanced Breast Cancer That Did Not Respond to Previous Treatment Phase 1/Phase 2
Completed NCT00244881 - A Phase II Study of AZD2171 in Breast Cancer Stage IV (10006202) Phase 2
Completed NCT00096434 - Sorafenib in Treating Patients With Metastatic Breast Cancer Phase 2
Terminated NCT01217411 - RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer Phase 1
Completed NCT01037790 - Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer Phase 2
Active, not recruiting NCT00791037 - Vaccine Therapy in Treating Patients With Stage IV Breast Cancer Phase 1/Phase 2
Completed NCT00559507 - Saracatinib in Treating Patients With Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed By Surgery Phase 2
Completed NCT00119262 - Bevacizumab and Combination Chemotherapy in Patients With Lymph Node Positive Breast Cancer Phase 2
Completed NCT00098605 - Lapatinib in Treating Brain Metastases in Patients With Stage IV Breast Cancer and Brain Metastases Phase 2
Terminated NCT00095888 - 3-AP and Gemcitabine in Treating Patients With Refractory Metastatic Breast Cancer Phase 2
Completed NCT00068588 - GTI-2040 and Capecitabine in Treating Patients With Metastatic Breast Cancer Phase 2
Terminated NCT00071942 - Vaccine Therapy in Treating Patients With Metastatic Breast Cancer Phase 1
Completed NCT02046421 - Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer Phase 1
Completed NCT01869764 - Omega-3 Fatty Acid in Treating Patients With Stage I-III Breast Cancer Phase 2
Completed NCT01720602 - Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy N/A
Terminated NCT01931709 - FDG PET and DCE-MRI in Predicting Response to Treatment in Patients With Breast Cancer N/A
Completed NCT01493310 - Nab-paclitaxel (Abraxane) With or Without Mifepristone in Patients With Advanced Breast Cancer Phase 1